The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Complement-targeted therapeutics
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441406 · Cited by 2,927
Wiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 1×
“Traditional drug discovery aims for small molecular entities with the potential for oral administration, yet many critical steps in the complement cascade are fundamentally based on large protein-protein interactions, which are challenging to influence with small molecule”
BackgroundPegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ROLE OF C5A IN INFLAMMATORY RESPONSES
Guo, R.-F., & Ward, P. A. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115835 · Cited by 1,021
Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C., Carson, G. R., Concino, M. F., Boyle, M. P., Roux, K. H., Weisfeldt, M. L., & Fearon, D. T. (1990) · Science · doi:10.1126/science.2371562 · Cited by 977
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C. P., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 907
The Role of Complement in Inflammatory Diseases From Behind the Scenes into the Spotlight
Markiewski, M. M., & Lambris, J. D. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070166 · Cited by 722
Self-citationAptamers come of age – at last
Bunka, D. H. J., & Stockley, P. G. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1458 · Cited by 695
Complement and coagulation: strangers or partners in crime?
Markiewski, M. M., Nilsson, B., Nilsson Ekdahl, K., Mollnes, T. E., & Lambris, J. D. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.02.006 · Cited by 645
Self-citationTeeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Hereditary angioedema with normal C1-inhibitor activity in women
Bork, K., Barnstedt, S.-E., Koch, P., & Traupe, H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02483-1 · Cited by 557
Structures of complement component C3 provide insights into the function and evolution of immunity
Janssen, B. J. C., Huizinga, E. G., Raaijmakers, H. C. A., Roos, A., Daha, M. R., Nilsson-Ekdahl, K., Nilsson, B., & Gros, P. (2005) · Nature · doi:10.1038/nature04005 · Cited by 541
The Role of Complement in the Development of Systemic Lupus Erythematosus
Manderson, A. P., Botto, M., & Walport, M. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104549 · Cited by 538
The Human Complement System in Health and Disease
(1998) · CRC Press eBooks · doi:10.1201/b14212 · Cited by 476
Chemotaxis Inhibitory Protein of Staphylococcus aureus, a Bacterial Antiinflammatory Agent
de Haas, C. J. C., Veldkamp, K. E., Peschel, A., Weerkamp, F., Van Wamel, W. J. B., Heezius, E. C. J. M., Poppelier, M. J. J. G., Van Kessel, K. P. M., & van Strijp, J. A. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031636 · Cited by 471
Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases
Rooijakkers, S. H. M., Ruyken, M., Roos, A., Daha, M. R., Presanis, J. S., Sim, R. B., van Wamel, W. J. B., van Kessel, K. P. M., & van Strijp, J. A. G. (2005) · Nature Immunology · doi:10.1038/ni1235 · Cited by 453
Function, structure and therapeutic potential of complement C5a receptors
Monk, P. N., Scola, A., Madala, P., & Fairlie, D. P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707332 · Cited by 404
Structure of C3b reveals conformational changes that underlie complement activity
Janssen, B. J. C., Christodoulidou, A., McCarthy, A., Lambris, J. D., & Gros, P. (2006) · Nature · doi:10.1038/nature05172 · Cited by 369
Self-citationInhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., & Evans, M. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00078-8 · Cited by 363
Wang, Y., Rollins, S. A., Madri, J. A., & Matis, L. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8955 · Cited by 360
Role of complement in neurodegeneration and neuroinflammation
BONIFATI, D., & KISHORE, U. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.03.007 · Cited by 313
Caliezi, C., Wuillemin, W. A., Zeerleder, S., Redondo, M., Eisele, B., & Hack, C. E. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01437-6 · Cited by 312
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Spitzer, D., Mitchell, L. M., Atkinson, J. P., & Hourcade, D. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2600 · Cited by 280
Sahu, A., Kay, B. K., & Lambris, J. D. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.2.884 · Cited by 264
Self-citationStructure of C3b in complex with CRIg gives insights into regulation of complement activation
Wiesmann, C., Katschke, K. J., Yin, J., Helmy, K. Y., Steffek, M., Fairbrother, W. J., McCallum, S. A., Embuscado, L., DeForge, L., Hass, P. E., et al. (2006) · Nature · doi:10.1038/nature05263 · Cited by 250
Therapeutic Inhibition of the Complement System
Makrides, S. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01349-8 · Cited by 246
C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a
Chen, N.-J., Mirtsos, C., Suh, D., Lu, Y.-C., Lin, W.-J., McKerlie, C., Lee, T., Baribault, H., Tian, H., & Yeh, W.-C. (2007) · Nature · doi:10.1038/nature05559 · Cited by 243
The pathophysiology of hereditary angioedema
Davis, A. E. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.05.007 · Cited by 235
The Role of Properdin in the Assembly of the Alternative Pathway C3 Convertases of Complement
Hourcade, D. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508928200 · Cited by 232
Complement and diseases: Defective alternative pathway control results in kidney and eye diseases
Zipfel, P. F., Heinen, S., Józsi, M., & Skerka, C. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.06.015 · Cited by 218
Complement: central to innate immunity and bridging to adaptive responses
Morgan, B. P., Marchbank, K. J., Longhi, M. P., Harris, C. L., & Gallimore, A. M. (2005) · Immunology Letters · doi:10.1016/j.imlet.2004.11.010 · Cited by 213
Rooijakkers, S. H. M., & van Strijp, J. A. G. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.06.011 · Cited by 207
Structure and flexibility of the multiple domain proteins that regulate complement activation
Kirkitadze, M. D., & Barlow, P. N. (2001) · Immunological Reviews · doi:10.1034/j.1600-065x.2001.1800113.x · Cited by 204
Proteases of the complement system
Sim, R. B., & Tsiftsoglou, S. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320021 · Cited by 202
X-ray Crystal Structure of C3d: A C3 Fragment and Ligand for Complement Receptor 2
Nagar, B., Jones, R. G., Diefenbach, R. J., Isenman, D. E., & Rini, J. M. (1998) · Science · doi:10.1126/science.280.5367.1277 · Cited by 201
Complement diversity: a mechanism for generating immune diversity?
Oriol Sunyer, J., Zarkadis, I. K., & Lambris, J. D. (1998) · Immunology Today · doi:10.1016/s0167-5699(98)01341-3 · Cited by 178
Self-citationComplement: more than a ‘guard’ against invading pathogens?
Mastellos, D. C., & Lambris, J. D. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02287-1 · Cited by 177
Self-citationA structural basis for complement inhibition by Staphylococcus aureus
Hammel, M., Sfyroera, G., Ricklin, D., Magotti, P., Lambris, J. D., & Geisbrecht, B. V. (2007) · Nature Immunology · doi:10.1038/ni1450 · Cited by 159
Self-citationTherapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration
Woodruff, T. M., Crane, J. W., Proctor, L. M., Buller, K. M., Shek, A., Vos, K. J. D., Pollitt, S., Williams, H. M., Shiels, I. A., Monk, P. N., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5814com · Cited by 154
Derivation of RNA aptamer inhibitors of human complement C5
Biesecker, G., Dihel, L., Enney, K., & Bendele, R. A. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00020-x · Cited by 152
Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics
Sahu, A., & Lambris, J. D. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)80299-4 · Cited by 144
Self-citationRecent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria
Hill, A., Richards, S. J., & Hillmen, P. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06554.x · Cited by 140
Two decades of orphan product development
Haffner, M. E., Whitley, J., & Moses, M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd919 · Cited by 137
Janssen, B. J. C., Halff, E. F., Lambris, J. D., & Gros, P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704587200 · Cited by 130
Self-citationMilder, F. J., Gomes, L., Schouten, A., Janssen, B. J. C., Huizinga, E. G., Romijn, R. A., Hemrika, W., Roos, A., Daha, M. R., & Gros, P. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1210 · Cited by 120
Holding T cells in check – a new role for complement regulators?
Longhi, M. P., Harris, C. L., Morgan, B. P., & Gallimore, A. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.12.008 · Cited by 113
Katragadda, M., Magotti, P., Sfyroera, G., & Lambris, J. D. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0603419 · Cited by 111
Self-citationSerres, J. D., Gröner, A., & Lindner, J. K. (2003) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2003.08.006 · Cited by 108
Katschke, K. J., Helmy, K. Y., Steffek, M., Xi, H., Yin, J., Lee, W. P., Gribling, P., Barck, K. H., Carano, R. A. D., Taylor, R. E., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070432 · Cited by 100
Phase I Safety, Tolerability, and Pharmacokinetic Study of Recombinant Human Mannan-Binding Lectin
Petersen, K. A., Matthiesen, F., Agger, T., Kongerslev, L., Thiel, S., Cornelissen, K., & Axelsen, M. (2006) · Journal of Clinical Immunology · doi:10.1007/s10875-006-9037-z · Cited by 92
Frei, Y., Lambris, J. D., & Stockinger, B. (1987) · Molecular and Cellular Probes · doi:10.1016/0890-8508(87)90022-3 · Cited by 90
Self-citationSahu, A., Morikis, D., & Lambris, J. D. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00212-2 · Cited by 90
Self-citationNarayana, S. V. L., Carson, M., El-Kabbani, O. A. L., Kilpatrick, J. M., Moore, D., Chen, X., Bugg, C. E., Volanakis, J. E., & DeLucas, L. J. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1021 · Cited by 83
Drug evaluation: the C5a receptor antagonist PMX-53.
Köhl, J. (2006) · PubMed · Cited by 80
Buerke, M., Schwertz, H., Seitz, W., Meyer, J., & Darius, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.5375 · Cited by 79
Selection, design, and engineering of therapeutic antibodies
Presta, L. G. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.08.003 · Cited by 72
Pexelizumab and the APEX AMI Trial
Armstrong, P. W., & Granger, C. B. (2007) · JAMA · doi:10.1001/jama.297.17.1881-b · Cited by 68
Potassium Iodide and Propranolol in Graves' Disease
Agostoni, A., Cicardi, M., Bergamaschini, L., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198008283030919 · Cited by 67
Targeting anticomplement agents
Smith, R. A. (2002) · Biochemical Society Transactions · doi:10.1042/bst0301037 · Cited by 61
Taube, C., Thurman, J. M., Takeda, K., Joetham, A., Miyahara, N., Carroll, M. C., Dakhama, A., Giclas, P. C., Holers, V. M., & Gelfand, E. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602357103 · Cited by 61
Complement Control Protein Modules in the Regulators of Complement Activation
Soares, D. C., & Barlow, P. N. (2005) · CRC Press eBooks · doi:10.1201/9780849350368-2 · Cited by 59
The Arthus Reaction in Rodents: Species-Specific Requirement of Complement
Szalai, A. J., Digerness, S. B., Agrawal, A. C., Kearney, J. F., Bucy, R. P., Niwas, S., Kilpatrick, J. M., Babu, Y. S., & Volanakis, J. E. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.463 · Cited by 57
Rittershaus, C. W., Thomas, L. J., MILLER, D. P., Picard, M. D., Geoghegan-Barek, K. M., Scesney, S. M., Henry, L. D., Sen, A. C., Bertino, A. M., Hannig, G., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.11237 · Cited by 55
Synthetic small-molecule complement inhibitors.
Holland, M. C., Morikis, D., & Lambris, J. D. (2004) · PubMed · Cited by 53
Self-citationHill, A., Ridley, S. H., Esser, D., Oldroyd, R. G., Cullen, M. J., Kareclas, P., Gallagher, S., Smith, G. P., Richards, S. J., White, J., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0782 · Cited by 53
Nielsen, E. W., Waage, C., Fure, H., Brekke, O., Sfyroera, G., Lambris, J. D., & Mollnes, T. E. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.10.003 · Cited by 48
Self-citationBypassing complement: evolutionary lessons and future implications
Atkinson, J. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28622 · Cited by 44
C1-inhibitor: an anti-inflammatory reagent with therapeutic potential
Kirschfink, M., & Mollnes, T. E. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.7.1073 · Cited by 40
Development of C5a receptor antagonists.
Wong, A. K., Taylor, S. M., & Fairlie, D. P. (1999) · PubMed · Cited by 39
The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass
Li, J. S., Jaggers, J. J., & Anderson, P. A. W. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.5.649 · Cited by 35
Bureeva, S. V., Andia-Pravdivy, J., Symon, A., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.03.002 · Cited by 33
Novel Therapies for Hereditary Angioedema
Zuraw, B. L. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.09.007 · Cited by 31
Drug design using the example of the complement system inhibitors' development
Bureeva, S. V., Andia-Pravdivy, J., & Kaplun, A. P. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03592-0 · Cited by 19
Lauterbach, M., Horstick, G., Plum, N., Lotz, J., Lauterbach, E., Weilemann, L. S., & Kempski, O. S. (2006) · Shock · doi:10.1097/01.shk.0000235093.83915.0b · Cited by 13
Rothberg, B. E. G., Peña, C. E., & Rothberg, J. M. (2005) · Wiley eBooks · doi:10.1002/9783527620982.ch4 · Cited by 6
Cited by
Complement: a key system for immune surveillance and homeostasis
Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010) · Nature Immunology · doi:10.1038/ni.1923 · Cited by 3,654
“The growing list of diseases that involve complement has fueled an interest in developing complement-targeted therapie”
BackgroundSelf-citationComplement regulators and inhibitory proteins
Zipfel, P. F., & Skerka, C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2620 · Cited by 1,264
Sarma, J. V., & Ward, P. A. (2011) · Cell and Tissue Research · doi:10.1007/s00441-010-1034-0 · Cited by 974
Modulation of the antitumor immune response by complement
Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., Coukos, G., & Lambris, J. D. (2008) · Nature Immunology · doi:10.1038/ni.1655 · Cited by 778
Self-citationComplement evasion by human pathogens
Lambris, J. D., Ricklin, D., & Geisbrecht, B. V. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1824 · Cited by 722
Self-citation
Metadata
- Authors
- Ricklin, D., & Lambris, J. D.
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1265-1275
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1970718615
- Cited by
- 481
- References
- 82
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.